Moderna (NASDAQ:MRNA) announced a significant milestone in global health security on April 22, 2026, with the dosing of the first participants in the United States and the United Kingdom for its Phase 3 clinical trial of mRNA-1018.
The investigational vaccine candidate is designed to protect against H5 pandemic influenza, a high-priority pathogen with significant pandemic potential.
The Phase 3 trial is an international, observer-blind, randomized study aiming to enroll approximately 4,000 adults aged 18 and older.
The primary objective is to evaluate the safety and immunogenicity of mRNA-1018 compared to an active comparator.
This late-stage trial is a critical step toward achieving licensure and establishing a rapid-response manufacturing capability for avian flu strains.
The development of mRNA-1018 is supported by the Coalition for Epidemic Preparedness Innovations (CEPI), which committed up to $54.3 million in December 2025 to accelerate the program.
This partnership underscores the strategic importance of mRNA technology in responding to emerging viral threats with greater speed and flexibility than traditional egg-based vaccine manufacturing.
Moderna’s pandemic readiness strategy is closely linked to its seasonal influenza portfolio.
Positive data from the mRNA-1018 study would complement the regulatory filings for mRNA-1010, the company’s seasonal flu candidate, which is currently under review by regulators in the U.S., EU, Canada, and Australia.
By leveraging the same platform for both seasonal and pandemic strains, Moderna aims to streamline the path to global licensure.
In a move to ensure equitable access, Moderna has pledged to reserve 20% of its H5 manufacturing capacity for low- and middle-income countries should the vaccine receive regulatory approval.
This commitment aligns with the company's broader mission to provide life-saving technology to underserved regions during public health emergencies.